PD-1 and TIM-3

Class

PD-1/TIM-3 bispecific monoclonal antibody

Pathway

Dual blockade of PD-1 and TIM-3 checkpoint receptors to restore antitumor T-cell activity and overcome/delay anti-PD-(L)1 resistance

PD-1 and TIM-3 are inhibitory receptors expressed on T cells that help restrain immune responses once T cells have been repeatedly activated, a state known as T-cell exhaustion. In cancer, tumors exploit these checkpoints to suppress the immune attack against them. Blocking PD-1 alone, an approach already used clinically, can restore some T-cell function, but many tumors escape this effect over time or never respond, in part because T cells upregulate additional inhibitory receptors, including TIM-3, as a backup brake. A bispecific antibody that blocks both PD-1 and TIM-3 simultaneously aims to address this compensatory mechanism, restoring antitumor T-cell activity more durably than blocking either receptor alone and potentially overcoming or delaying resistance that emerges with single-agent checkpoint blockade. This dual-blockade strategy is broadly relevant across solid tumors and hematologic malignancies where checkpoint-driven immune suppression limits the effectiveness of the body's own antitumor response, and where resistance to existing checkpoint inhibitors is a recognized clinical problem. By engaging two distinct but complementary inhibitory pathways with one molecule, this class of agent seeks to achieve broader disinhibition of exhausted T cells than a single-target antibody.